IRIS
CANONICA, GIORGIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 78.937
AS - Asia 6.631
NA - Nord America 3.022
SA - Sud America 518
AF - Africa 109
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 3
Totale 89.224
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 77.753
SG - Singapore 3.065
US - Stati Uniti d'America 2.801
CN - Cina 1.716
VN - Vietnam 940
FR - Francia 625
BR - Brasile 319
BD - Bangladesh 246
HK - Hong Kong 220
FI - Finlandia 155
DE - Germania 125
AR - Argentina 89
CA - Canada 78
MX - Messico 78
JP - Giappone 74
GB - Regno Unito 58
IQ - Iraq 58
IN - India 57
CH - Svizzera 51
NL - Olanda 40
ID - Indonesia 39
PH - Filippine 28
EC - Ecuador 26
CO - Colombia 25
MA - Marocco 25
TH - Thailandia 22
KR - Corea 19
RU - Federazione Russa 19
ZA - Sudafrica 19
VE - Venezuela 18
UZ - Uzbekistan 17
IE - Irlanda 16
PK - Pakistan 16
ES - Italia 14
TR - Turchia 14
JO - Giordania 13
UA - Ucraina 13
CL - Cile 12
EG - Egitto 12
PY - Paraguay 12
JM - Giamaica 11
NP - Nepal 11
TT - Trinidad e Tobago 10
TW - Taiwan 10
AT - Austria 9
DZ - Algeria 9
KE - Kenya 9
MY - Malesia 8
SE - Svezia 8
TN - Tunisia 8
BO - Bolivia 7
GT - Guatemala 7
LT - Lituania 7
PA - Panama 7
SA - Arabia Saudita 7
DO - Repubblica Dominicana 6
HN - Honduras 6
KZ - Kazakistan 6
LB - Libano 6
NG - Nigeria 6
OM - Oman 6
AZ - Azerbaigian 5
CR - Costa Rica 5
PL - Polonia 5
UY - Uruguay 5
AE - Emirati Arabi Uniti 4
BA - Bosnia-Erzegovina 4
IL - Israele 4
MD - Moldavia 4
MM - Myanmar 4
NI - Nicaragua 4
PE - Perù 4
PT - Portogallo 4
SN - Senegal 4
AL - Albania 3
AU - Australia 3
BB - Barbados 3
BG - Bulgaria 3
BY - Bielorussia 3
CY - Cipro 3
HU - Ungheria 3
RS - Serbia 3
SY - Repubblica araba siriana 3
BH - Bahrain 2
CZ - Repubblica Ceca 2
ET - Etiopia 2
GH - Ghana 2
KG - Kirghizistan 2
NE - Niger 2
PR - Porto Rico 2
PS - Palestinian Territory 2
RO - Romania 2
SV - El Salvador 2
XK - ???statistics.table.value.countryCode.XK??? 2
AM - Armenia 1
AO - Angola 1
BE - Belgio 1
BF - Burkina Faso 1
BJ - Benin 1
BQ - ???statistics.table.value.countryCode.BQ??? 1
Totale 89.202
Salva come PNG Salva come JPEG
Città #
Genova 54.592
Genoa 13.001
Rapallo 5.921
Vado Ligure 3.836
Singapore 1.431
San Jose 1.243
Lauterbourg 613
Ho Chi Minh City 250
Ashburn 232
Hanoi 227
Hong Kong 214
New York 200
Beijing 191
Helsinki 151
Santa Clara 108
Frankfurt am Main 102
Bordighera 84
Council Bluffs 72
Tokyo 66
Los Angeles 51
Mexico City 51
Zurich 46
Haiphong 45
Da Nang 40
Tianjin 38
Dallas 29
Amsterdam 28
Rome 27
Naples 24
Milan 23
Baghdad 21
São Paulo 21
Biên Hòa 20
Buffalo 19
Chicago 19
City of London 19
Shanghai 19
Guangzhou 18
Can Tho 17
Dublin 17
Hải Dương 17
Cardiff 16
Phoenix 15
Orem 14
Tashkent 14
Turin 14
Jakarta 13
Des Moines 12
Toronto 12
Atlanta 11
Bangkok 11
Montreal 11
Nuremberg 11
Amman 10
Belo Horizonte 9
Boardman 9
Guayaquil 9
Quito 9
Bologna 8
Dhaka 8
Florence 8
Jersey City 8
Nairobi 8
Panama City 8
Asunción 7
Cagliari 7
Johannesburg 7
Queens 7
Rio de Janeiro 7
Thái Nguyên 7
Vienna 7
Brasília 6
Buenos Aires 6
Calgary 6
Denver 6
Houston 6
Malang 6
Nha Trang 6
Pasadena 6
Philadelphia 6
Porto Alegre 6
San Francisco 6
Stockholm 6
Vancouver 6
Zhengzhou 6
Baku 5
Bengaluru 5
Bergamo 5
Bogotá 5
Brooklyn 5
Bình Phước 5
Bắc Giang 5
Bắc Ninh 5
Caracas 5
Changsha 5
Chongqing 5
Delhi 5
East Gwillimbury 5
Guarulhos 5
Guatemala City 5
Totale 83.599
Salva come PNG Salva come JPEG
Nome #
360 degree perspective on allergic rhinitis management in Italy: A survey of GPs, pharmacists and patients 223
A Review of the Evidence from Comparative Studies of Levocetirizine and Desloratadine for the Symptoms of Allergic Rhinitis 212
Levocetirizine in persistent allergic rhinitis and asthma: effects on symptoms, quality of life and inflammatory parameters. 209
Adhesion molecules in allergy. 208
Administration of a polyvalent mechanical bacterial lysate to elderly patients with COPD: Effects on circulating T, B and NK cells. 207
The perception of Obstructive Sleep Apnoea/Hypopnoea Syndrome (OSAHS) among Italian general practitioners 207
Galectin-3: An early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36 months 206
A critical evaluation of Anti-IL-13 and Anti-IL-4 strategies in severe asthma 204
A three-year double-blind placebo-controlled study with specific oral immunotherapy to Dermatophagoides: evidence of safety and efficacy in paediatric patients. 203
Cetirizine reduces inflammatory cell recruitment and ICAM-1 (or CD54) expression on conjunctival epithelium in both early and late phase reactions after allergen-specific challenge. 202
Genuair® Usability Test: Results of a National Public Survey of the Elderly 200
Personalized medicine in allergy 198
Molecular phenotyping and biomarker development: Are we on our way towards targeted therapy for severe asthma? 197
Allergen-driven HLA-G expression and secretion in peripheral blood mononuclear cells from allergic rhinitis patients 196
A double-blind, placebo-controlled study on the diagnostic accuracy of an electrodermal test in allergic subjects. 193
The bacterial lysate Lantigen B reduces the number of acute episodes in patients with recurrent infections of the respiratory tract: the results of a double blind, placebo controlled, multicenter clinical trial 192
A new tool to assess and monitor the burden of chronic cough on quality of life: Chronic Cough Impact Questionnaire. 191
Anti-IL-5 and IL-5Ra: Efficacy and safety of new therapeutic strategies in severe uncontrolled asthma 189
Mepolizumab in the management of severe eosinophilic asthma in adults: Current evidence and practical experience 189
A 4-year trial of tiotropium in chronic obstructive pulmonary disease. 188
Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life 187
Allergic Rhinitis and its Impact on Asthma (ARIA) Classes in MASK-air Users 187
60Co therapy as an "allergic breakthrough" in a case of food allergy. 185
Local Side Effects of Sublingual and Oral Immunotherapy 185
Absorption and distribution kinetics of the major Parietaria judaica allergen (Par j 1) administered by noninjectable routes in healthy human beings. 183
CD40 on adult human airway epithelial cells: expression and proinflammatory effects 183
Analysis of the drop-out rate in patients receiving mepolizumab for severe asthma in real life 182
Changed allergy pattern in outpatients 181
A new protocol for specific oral tolerance induction in children with IgE-mediated cow's milk allergy. 180
The administration of a polyvalent mechanical bacterial lysate in elderly patients with COPD results in serological signs of an efficient immune response associated with a reduced number of acute episodes 180
A WAO-ARIA-GA2LEN consensus document on molecular-based allergy diagnostics 180
T cell activation through different membrane structures (T3/Ti, T11, T44) and frequency analysis of proliferating and interleukin-2 producer T lymphocyte precursors in aged individuals. 179
Antiallergic drugs and quality of life. 178
Functionally relevant decreases in activatory receptor expression on NK cells are associated with pulmonary tuberculosis in vivo and persist after successful treatment. 177
Chronic Urticaria Patient Perspective (CUPP): The First Validated Tool for Assessing Quality of Life in Clinical Practice 177
Inhibition of adhesion molecules by budesonide on a human epithelial cell line (lung carcinoma) 177
Methods report on the development of the 2013 revision and update of the EAACI/GA2 LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria 177
Sleep complaints and sleep breathing disorders in upper and lower obstructive lung diseases 176
Sublingual immunotherapy abrogates seasonal bronchial hyperresponsiveness in children with Parietaria-induced respiratory allergy: a randomized controlled trial. 175
Allergic subjects express intercellular adhesion molecule-1 (ICAM-1 or CD54) on epithelial cells of conjunctiva allergen challenge. 174
Eligibility for treatment with omalizumab in Italy and Germany 174
A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU-QoL). 173
COPD treatment: Real life and experimental effects on peripheral NK cells, their receptors expression and their IFN-γ secretion. 173
Allergic diseases and their impact on quality of life. 172
Efficacy of mometasone furoate nasal spray in the treatment of allergic rhinitis. Meta-analysis of randomized, double-blind, placebo-controlled, clinical trials. 171
A role for the intranasal formulation of azelastine hydrochloride/fluticasone propionate in the treatment of allergic rhinitis 171
CD4+CD25highCD127- regulatory T-cells in COPD: Smoke and drugs effect 171
Basi Patogenetiche ed anatomopatologiche della flogosi allergica nell’asma bronchiale 170
Catching allergy by a simple questionnaire 170
Clara cell 16 protein in COPD sputum: A marker of small airways damage? 169
Inhaled Corticosteroids Safety and Adverse Effects in Patients with Asthma 169
Nasal immunotherapy to Parietaria: evidence of reduction of local allergic inflammation. 168
New insights into airway remodelling in asthma and its possible modulation. 168
Allergic rhinitis and asthma ad hoc survey: clinical and psychological perspectives. 168
ARIA-ITALY multidisciplinary consensus on nasal polyposis and biological treatments 168
Proteomics of bronchial biopsies: galectin-3 as a predictive biomarker of airway remodelling modulation in omalizumab-treated severe asthma patients. 167
30 Years Of Sublingual Immunotherapy 167
T cell activation surface markers and autologous mixed lymphocyte reaction do not differ in true and pseudo food allergy. 165
When to stop biologicals. Severe asthma exacerbation after mepolizumab discontinuation 165
Inflammatory and mechanical factors of allergen-induced bronchoconstriction in mild asthma and rhinitis 164
The additional values of microarray allergen assay in the management of polysensitized patients with respiratory allergy. 164
Biomarkers and severe asthma: a critical appraisal. 164
Viruses and bacteria in acute asthma exacerbations--a GA² LEN-DARE systematic review. 163
Allergen-specific conjunctival challenge in children with allergic asthma: a clinical tool. 163
100 years of immunotherapy: the Monaco charter. under the high patronage of His Serene Highness Prince Albert II of Monaco. 163
Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate, severe, or very severe chronic obstructive pulmonary disease (COPD) according to the GOLD spirometric classification: A multicentre, double-blind, randomised, controlled, phase IV study (AIACE study: Advanced Immunological Approach in COPD Exacerbation) 162
Comparison of the colony forming capacities of human T lymphocyte subpopulations. 161
Biomarker discovery in asthma and COPD by proteomic approaches 161
Pidotimod: The state of art 161
The relationship between allergen immunotherapy and omalizumab for treating asthma 161
Umeclidinium for the treatment of uncontrolled asthma 161
Biosimilars in allergic diseases 161
Adherence to treatment: assessment of an unmet need in asthma. 160
Manifesto on small airway involvement and management in asthma and chronic obstructive pulmonary disease: an Interasma (Global Asthma Association - GAA) and World Allergy Organization (WAO) document endorsed by Allergic Rhinitis and its Impact on Asthma (ARIA) and Global Allergy and Asthma European Network (GA2LEN) 160
Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients. 160
Recommendations for assessing patient-reported outcomes and health-related quality of life in patients with urticaria: a GA(2) LEN taskforce position paper. 160
Aerobiologic particle sampling by a new personal collector (Partrap FA52) in comparison to the Hirst (Burkard) sampler. 159
The ARGA study with general practitioners: Impact of medical education on asthma/rhinitis management 159
Serum cytotoxic T lymphocyte-associated antigen 4 in hymenoptera venom allergy and its modulation by specific immunotherapy 159
Focus on cat allergen (Fel d 1): immunological and aerodynamic characteristics, modality of airway sensitization and avoidance strategies. 159
Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. 158
Standards for practical allergen-specific immunotherapy. 158
Allergen-specific nasal challenge: response kinetics of clinical and inflammatory events to rechallenge. 158
Allergenius, an expert system for the interpretation of allergen microarray results 158
Pharmacovigilance of drug allergy and hypersensitivity using the ENDA-DAHD database and the GALEN platform. The Galenda project. 157
Continuous versus on demand treatment with cetirizine for allergic rhinitis. 157
Benefit of SLIT and SCIT for Allergic Rhinitis and Asthma 157
MK-8237: a house dust mite vaccine for treating allergic rhinitis, asthma and atopic dermatitis 157
Adherence to asthma treatments: 'We know, we intend, we advocate' 156
The international survey on the management of allergic rhinitis by physicians and patients (ISMAR) 155
Appropriateness in allergic respiratory diseases health care in Italy: Definitions and organizational aspects 155
[Anti-leukotriene agents: rationale for and prospects of use]. 155
Azelastine eye drops reduce and prevent allergic conjunctival reaction and exert anti-allergic activity. 155
Development and implementation of guidelines in allergic rhinitis – an ARIA-GA2LEN paper. 155
Formoterol by pressurized metered-dose aerosol or dry powder on airway obstruction and lung hyperinflation in partially reversible COPD 154
Treatment of exercise-induced asthma, respiratory and allergic disorders in sports and the relationship to doping: Part II of the report from the Joint Task Force of European Respiratory Society (ERS) and European Academy of Allergy and Clinical Immunology (EAACI) in cooperation with GA(2)LEN 153
Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. 153
GA2LEN (Global Allergy and Asthma European Network) addresses the allergy and asthma 'epidemic'. 153
Antiallergic activity of topical lodoxamide on in vivo and in vitro models. 153
Molecular diagnosis and precision medicine in allergy management 153
Totale 17.331
Salva come PNG Salva come JPEG
Categoria #
all - tutte 268.336
article - articoli 265.657
book - libri 0
conference - conferenze 282
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 2.397
Totale 536.672
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021415 0 0 0 0 0 0 0 0 0 0 0 415
2021/20228.170 216 487 428 1.298 189 694 666 1.804 336 710 278 1.064
2022/20237.156 791 301 38 688 1.146 1.568 13 565 1.426 62 466 92
2023/20242.797 193 537 62 272 242 453 132 129 151 52 146 428
2024/20258.865 121 857 358 555 1.341 948 784 1.158 340 508 722 1.173
2025/202615.868 1.663 444 1.011 1.255 1.867 2.150 3.005 665 1.048 1.367 843 550
Totale 89.838